Best’s Market Segment Report: Reinsurance Solutions Becoming More Viable for Health Insurers

Ceded U.S. health-insurance premiums placed with reinsurers rose to $203 billion in 2025 from $59 billion in 2016, an increase of more than 300%, according to AM Best. The report indicates reinsurance solutions are becoming increasingly viable for health insurers, supporting greater risk transfer and balance-sheet management across the sector.

Analysis

The investable implication is a gradual transfer of volatility and capital intensity from primary managed-care balance sheets to global reinsurers. For UNH, ELV, CI, HUM and CVS, greater risk transfer can reduce statutory-capital strain and smooth adverse medical-cost development, but it also caps upside from favorable utilization trends; the earnings benefit is therefore more about lower tail risk and potential buyback capacity than a step-change in underwriting margin. This is most relevant for Medicare Advantage and other products with volatile severity risk, where reserve adequacy and regulatory capital requirements have become binding constraints.

RGA, MURGY, SSREY, HVRRY and SCRYY are the more direct beneficiaries, although the market should not treat additional premium as automatically accretive. Health reinsurance is exposed to adverse selection: cedants tend to retain predictable profitable cohorts and transfer high-severity or deteriorating blocks, so combined-ratio deterioration can emerge with a lag of 2-6 quarters. The key near-term question is whether pricing and attachment points are rising faster than medical trend; without disclosure on rate adequacy, renewal retention and reserve development, this is an industry-structure signal rather than a standalone earnings catalyst.

Consensus may over-credit primary insurers for reduced volatility. If reinsurance costs rise at renewals, managed-care companies could face a delayed margin headwind precisely when reimbursement rates are already under pressure; reinsurers with disciplined underwriting would capture that economics. Conversely, a benign utilization environment would make ceded protection look expensive, allowing primary carriers to retain more risk and limiting reinsurer premium growth over the next 12-18 months.

Key Decisions for Investors

• Maintain a watch-list long bias in RGA versus HUM over the next 6-12 months, but do not initiate solely on this data point. Enter only if RGA reports health premium growth alongside stable or improving health claim experience; thesis is falsified by adverse reserve development or a meaningful combined-ratio miss.
• For managed-care exposure, prefer UNH and ELV over HUM and CVS on a 3-9 month horizon: larger, diversified platforms can use reinsurance as capital optimization rather than as a defensive response to a concentrated Medicare Advantage margin problem. Reassess after 2026 Medicare rate and benefit disclosures.
• Set an earnings-season alert for ceded-premium growth, reinsurance expense, risk-based-capital ratios and reserve releases across UNH, ELV, CI, HUM and CVS. A sharp increase in ceded premium combined with worsening medical-loss-ratio guidance would be a negative signal, not evidence of de-risking.
• Avoid broad long positions in P&C-focused reinsurers such as ACGL, RNR and EG based on this theme; their direct exposure to U.S. health risk transfer is less clear, and the relevant upside is concentrated in life/health reinsurance specialists.